Atogepant, the first oral preventive treatment for chronic migraine
- PMID: 37516124
- DOI: 10.1016/S0140-6736(23)01462-9
Atogepant, the first oral preventive treatment for chronic migraine
Conflict of interest statement
KAH reports grants from Lundbeck Foundation Fellowship (R345-2020-1977) and personal fees from TEVA for lectures on CGRP, outside the submitted work. LE reports personal fees from Amgen for lectures on CGRP, personal fees from Novartis for lectures on CGRP, personal fees from TEVA for lectures on CGRP, and grants from Allergan on Botox, outside the submitted work.
Comment on
-
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2023 Sep 2;402(10404):775-785. doi: 10.1016/S0140-6736(23)01049-8. Epub 2023 Jul 26. Lancet. 2023. PMID: 37516125 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical